search
Back to results

Laryngeal Allograft Transplantation

Primary Purpose

Larynx Stenosis, Larynx Disease, Laryngectomy

Status
Enrolling by invitation
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Larynx Allograft Transplantation
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Larynx Stenosis focused on measuring severe laryngotracheal dysfunction

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Potential subjects for this study include patients with severe laryngeal dysfunction or a previous laryngectomy. For the purposes of this study, severe laryngeal dysfunction is defined as the loss of normal laryngeal function resulting in significant dysphonia, dysphagia, or dyspnea.

Inclusion Criteria:

  • Ages 18 years and older
  • Male or Female
  • One of the following:

    • Severe laryngeal dysfunction as described above
    • Laryngeal stenosis
    • 5 years or longer s/p definitive management for head and neck cancer
    • Laryngeal cancer requiring total laryngectomy in a patient already on immunosuppression
    • Low-grade chondrosarcoma requiring total laryngectomy
  • Ability to obtain informed consent from the patient

Exclusion Criteria:

Poor surgical candidacy secondary to poor physical/mental health as determined by a pre-operative medical evaluation

General medical status

  • Pregnancy
  • Any systemic disease which would alter life expectancy

    • Active neoplastic disease, not considered yet to be cured (Exceptional cases will be considered in case by case discussion)Less than 5 years s/p definitive management for cancer
    • Cancer within the last 5 years (Exceptional cases will be considered in case by case discussion)
    • Obesity (Body Mass Index >29 - 30)(Exceptional cases will be considered on a case by case basis)
    • Cachexia (BMI<18)(Exceptional cases will be considered on a case by case basis) Significant renal dysfunction (Creatinine clearance < 50 ml/min.)
    • Significant hepatic dysfunction
    • Significant kidney damage
    • Unmanageable infections
    • Unable to participate in preoperative exercise training
    • Unable to be weaned to equal or less than 10 mg/day of steroids
    • Untreatable cardiac disease
    • Active neuromuscular disease
    • History of recurrent aspiration or active, unmanageable Gastro-Esophageal Reflux
    • Patients with active connective tissue diseases (exceptions to be considered in a case by case basis)
    • Patients unable to achieve > 600 feet in a 6 minute walk test (exceptions to be considered in a case by case basis)
    • Patients considered having active immunodeficiency disorders (exceptions to be considered in a case by case basis)
    • Multiple co-morbidities that would make transplantation prohibitively risky
  • Psychosocial parameters

    • Severe mental retardation, psychosis, depression or organic brain syndrome
    • Uncontrolled diabetes mellitus. Once HbA1C < 7, reevaluate for candidacy.
    • Active substance use within 6 months
    • Active smoking within 6 months
    • Active alcoholism within 6 months
    • Inability to comply with transplant-related management and medical follow-up
    • Any other circumstances that deem the candidate high risk from a psychosocial perspective

Sites / Locations

  • Mayo Clinic in Arizona

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Larynx Allograft Transplantation

Arm Description

Cadaveric laryngotracheal transplantation

Outcomes

Primary Outcome Measures

Survival of the allograft at the one-year visit.
Survival of the allograft as indicated by histological rejection grading.

Secondary Outcome Measures

Swallowing without aspiration at the one-year visit.
Voice Evaluation
Standard voice evaluation will include voice recordings, acoustic and aerodynamic measurements as compared to baseline measurements.
Pulmonary function
Pulmonary function values within normal range.
Ability to have tracheotomy tube decannulated
Ability to have tracheotomy tube decannulated after successful capping trials.

Full Information

First Posted
August 7, 2017
Last Updated
July 3, 2023
Sponsor
Mayo Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT03269396
Brief Title
Laryngeal Allograft Transplantation
Official Title
A Prospective Nonrandomized Study of Laryngeal Allograft Transplantation Clinical Investigation
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
May 1, 2022 (Actual)
Primary Completion Date
May 2028 (Anticipated)
Study Completion Date
May 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this proposed study is to obtain safety and efficacy data on human laryngeal allograft transplantation in an effort to safely use these procedures as a viable reconstructive option for patients with severe laryngeal or laryngotracheal incompetence.
Detailed Description
Patients with severe laryngeal or laryngotracheal incompetence without other reconstructive options will be considered for cadaveric laryngotracheal transplantation. Data will be collected from 10 patients and will include length of hospital stay, short-term complications, long-term complications, hospital readmission, return trips to the operating room (OR), rejection episodes and severity, swallowing function, ability to have tracheotomy tube decannulated, voice parameters, pulmonary function, development of anti-donor antibodies, and quality of life scores.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Larynx Stenosis, Larynx Disease, Laryngectomy, Larynx, Larynx Fracture
Keywords
severe laryngotracheal dysfunction

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Larynx Allograft Transplantation
Arm Type
Experimental
Arm Description
Cadaveric laryngotracheal transplantation
Intervention Type
Procedure
Intervention Name(s)
Larynx Allograft Transplantation
Intervention Description
This study is a prospective clinical trial designed to assess the efficacy and safety of laryngeal transplantation. A total of 10 patients will be enrolled over a five-year timeframe. Study length is 5 years.
Primary Outcome Measure Information:
Title
Survival of the allograft at the one-year visit.
Description
Survival of the allograft as indicated by histological rejection grading.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Swallowing without aspiration at the one-year visit.
Time Frame
1 year
Title
Voice Evaluation
Description
Standard voice evaluation will include voice recordings, acoustic and aerodynamic measurements as compared to baseline measurements.
Time Frame
1 year
Title
Pulmonary function
Description
Pulmonary function values within normal range.
Time Frame
1 year
Title
Ability to have tracheotomy tube decannulated
Description
Ability to have tracheotomy tube decannulated after successful capping trials.
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Potential subjects for this study include patients with severe laryngeal dysfunction or a previous laryngectomy. For the purposes of this study, severe laryngeal dysfunction is defined as the loss of normal laryngeal function resulting in significant dysphonia, dysphagia, or dyspnea. Inclusion Criteria: Ages 18 years and older Male or Female One of the following: Severe laryngeal dysfunction as described above Laryngeal stenosis 5 years or longer s/p definitive management for head and neck cancer Laryngeal cancer requiring total laryngectomy in a patient already on immunosuppression Low-grade chondrosarcoma requiring total laryngectomy Ability to obtain informed consent from the patient Exclusion Criteria: Poor surgical candidacy secondary to poor physical/mental health as determined by a pre-operative medical evaluation General medical status Pregnancy Any systemic disease which would alter life expectancy Active neoplastic disease, not considered yet to be cured (Exceptional cases will be considered in case by case discussion)Less than 5 years s/p definitive management for cancer Cancer within the last 5 years (Exceptional cases will be considered in case by case discussion) Obesity (Body Mass Index >29 - 30)(Exceptional cases will be considered on a case by case basis) Cachexia (BMI<18)(Exceptional cases will be considered on a case by case basis) Significant renal dysfunction (Creatinine clearance < 50 ml/min.) Significant hepatic dysfunction Significant kidney damage Unmanageable infections Unable to participate in preoperative exercise training Unable to be weaned to equal or less than 10 mg/day of steroids Untreatable cardiac disease Active neuromuscular disease History of recurrent aspiration or active, unmanageable Gastro-Esophageal Reflux Patients with active connective tissue diseases (exceptions to be considered in a case by case basis) Patients unable to achieve > 600 feet in a 6 minute walk test (exceptions to be considered in a case by case basis) Patients considered having active immunodeficiency disorders (exceptions to be considered in a case by case basis) Multiple co-morbidities that would make transplantation prohibitively risky Psychosocial parameters Severe mental retardation, psychosis, depression or organic brain syndrome Uncontrolled diabetes mellitus. Once HbA1C < 7, reevaluate for candidacy. Active substance use within 6 months Active smoking within 6 months Active alcoholism within 6 months Inability to comply with transplant-related management and medical follow-up Any other circumstances that deem the candidate high risk from a psychosocial perspective
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David G Lott
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic in Arizona
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85259
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://www.mayo.edu/research/clinical-trials
Description
Mayo Clinic Clinical Trials

Learn more about this trial

Laryngeal Allograft Transplantation

We'll reach out to this number within 24 hrs